# | Title | Journal | Year | Citations |
---|
1 | Diagnostic criteria and classification of mastocytosis: a consensus proposal | Leukemia Research | 2001 | 1,020 |
2 | Establishment of an immature mast cell line from a patient with mast cell leukemia | Leukemia Research | 1988 | 696 |
3 | Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference | Leukemia Research | 2007 | 478 |
4 | Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI | Leukemia Research | 2003 | 473 |
5 | A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells | Leukemia Research | 1984 | 391 |
6 | 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells | Leukemia Research | 1983 | 308 |
7 | In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy | Leukemia Research | 2009 | 305 |
8 | Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy | Leukemia Research | 2001 | 299 |
9 | Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) | Leukemia Research | 2007 | 288 |
10 | Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients | Leukemia Research | 2000 | 279 |
11 | Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H | Leukemia Research | 1998 | 262 |
12 | Human CD38: a (r)evolutionary story of enzymes and receptors | Leukemia Research | 2001 | 258 |
13 | A new leukemia cell line with philadelphia chromosome characterized as basophil precursors | Leukemia Research | 1985 | 255 |
14 | BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review | Leukemia Research | 2010 | 252 |
15 | Cyclin: A nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells | Leukemia Research | 1984 | 235 |
16 | MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation | Leukemia Research | 1999 | 233 |
17 | Properties and usefulness of the original K-562 human myelogenous leukemia cell line | Leukemia Research | 1979 | 226 |
18 | HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells | Leukemia Research | 2006 | 223 |
19 | Hematopoietic-specific microRNA expression in human cells | Leukemia Research | 2006 | 222 |
20 | The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells | Leukemia Research | 1994 | 217 |
21 | Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria | Leukemia Research | 2003 | 217 |
22 | Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings | Leukemia Research | 2001 | 211 |
23 | Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis | Leukemia Research | 2001 | 206 |
24 | The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis | Leukemia Research | 2009 | 203 |
25 | Phenotypic heterogeneity and cellular origins of T cell malignancies | Leukemia Research | 1981 | 202 |
26 | Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? | Leukemia Research | 2013 | 198 |
27 | Clinical and histopathological aspects of cutaneous mastocytosis | Leukemia Research | 2001 | 194 |
28 | Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes | Leukemia Research | 1996 | 189 |
29 | Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma: Dissociation between phenotype and genotype | Leukemia Research | 1989 | 187 |
30 | Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia | Leukemia Research | 1981 | 185 |
31 | Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1 | Leukemia Research | 2007 | 183 |
32 | Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM | Leukemia Research | 2010 | 183 |
33 | Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis | Leukemia Research | 1996 | 175 |
34 | The relevance of a geriatric assessment for elderly patients with a haematological malignancy – A systematic review | Leukemia Research | 2014 | 173 |
35 | Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells | Leukemia Research | 1984 | 171 |
36 | Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed | Leukemia Research | 2011 | 171 |
37 | Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry | Leukemia Research | 2011 | 169 |
38 | Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid | Leukemia Research | 2005 | 167 |
39 | Non-hodgkin's lymphoma: Case control epidemiological study in Yorkshire | Leukemia Research | 1988 | 166 |
40 | A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia | Leukemia Research | 1980 | 165 |
41 | Identification of a membrane glycoprotein associated with haemopoietic progenitor cells | Leukemia Research | 1985 | 165 |
42 | Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project | Leukemia Research | 2007 | 164 |
43 | The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells | Leukemia Research | 2010 | 164 |
44 | Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study | Leukemia Research | 2010 | 164 |
45 | The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future | Leukemia Research | 2004 | 161 |
46 | Endogenous inhibitors of angiogenesis | Leukemia Research | 2009 | 155 |
47 | Problems in the classification of CMML—dysplastic versus proliferative type | Leukemia Research | 1998 | 154 |
48 | A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow | Leukemia Research | 1985 | 153 |
49 | ETV6 fusion genes in hematological malignancies: A review | Leukemia Research | 2012 | 153 |
50 | CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes | Leukemia Research | 2010 | 150 |